Acro Biomedical Co (ROCO:6748) Research & Development: NT$30.83 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6748 Acro Biomedical Co Ltd ROCO:6748
66 GF Score
Price NT$295.50
GF Value NT$32.13
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Acro Biomedical Co Research & Development?

Acro Biomedical Co ROCO:6748 +16.57% 66 Research & Development is NT$30.83 Mil as of Dec. 2025. GuruFocus rates ROCO:6748 with a GF Score™ of 66/100 and a GF Value™ of NT$32.13 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Acro Biomedical Co's Research & Development for the six months ended in Dec. 2025 was NT$16.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$30.83 Mil.

Acro Biomedical Co  (ROCO:6748) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Acro Biomedical Co Research & Development Related Terms

Acro Biomedical Co Research & Development Historical Data

* Premium members only.

The historical data trend for Acro Biomedical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acro Biomedical Co Research & Development Chart

Acro Biomedical Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 26.04 27.85 28.64 25.72 30.83

Acro Biomedical Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.54 12.32 13.39 14.83 16.00
ROCO:6748
66GF Score
Acro Biomedical Co Ltd ROCO:6748
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acro Biomedical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$30.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$30.83 Mil mean?
Acro Biomedical Co (ROCO:6748) has a Research & Development of NT$30.83 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Acro Biomedical Co and its competitors.
Is Acro Biomedical Co's Research & Development too high?
Acro Biomedical Co's current Research & Development is NT$30.83 Mil. Overall, Acro Biomedical Co has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acro Biomedical Co's Research & Development compare to VRTX and REGN?
Acro Biomedical Co's Research & Development of NT$30.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Acro Biomedical Co and its competitors. Acro Biomedical Co's current Research & Development is NT$30.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acro Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Acro Biomedical Co (ROCO:6748) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$32.13, compared to a current price of NT$295.50 — trading 819.7% above its estimated fair value. The current Research & Development is NT$30.83 Mil. Acro Biomedical Co's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Acro Biomedical Co (ROCO:6748), the current Research & Development is NT$30.83 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Acro Biomedical Co (ROCO:6748) Overvalued in 2026?

Based on GuruFocus' analysis, Acro Biomedical Co stock appears to be overvalued. The current stock price of NT$295.50 is trading 819.7% above its estimated GF Value™ of NT$32.13. GuruFocus considers Acro Biomedical Co to be Significantly Overvalued.

Key valuation signals for ROCO:6748:

  • Research & Development: NT$30.83 Mil
  • GF Value™: NT$32.13 vs. price of NT$295.50 (819.7% above fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the ROCO:6748 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Acro Biomedical Co Business Description

Address 3rd Floor, No. 57, Luke 2nd Road, Luzhu District, Kaohsiung, TWN
Acro Biomedical Co Ltd is a company whose technical team integrates the Research and development capabilities of Taiwan's major scientific research units and medical centers to jointly develop equipment for repairing organs and tissues in various parts of the human body. It mainly focuses on orthopedics, dentistry, cardiovascular specialists, ophthalmology, surgery, wound care, Medical equipment used in sports injuries and other specialties.
66GF Score

Get the complete analysis for ROCO:6748

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$295.50
Price
NT$32.13
GF Value